Eli Lilly, Novo Nordisk file competing new weight-loss drugs with the FDA that could be game changers in obesity medicine

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...
BioPharma Dive

Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

Eli Lilly cuts price of diabetes, weight-loss drugs in Canada, Globe and Mail reports

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Eli Lilly Scores Another Major Win: Time to Buy?

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees 'Room For Stock Upside' With $3 Billion In Sales By 2026Mounjaro Maker Eli Lilly Improves In Quality As Bof…

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

Eli Lilly or Merck: Where Should Investors Put Their Money?

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Where Will Eli Lilly Be in 10 Years?

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...